Tejnaksh Healthcare Ltd vs Transgene Biotek Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Tejnaksh Healthcare Ltd is ₹ 11.78 as of 23 Oct 15:30 . The P/E Ratio of Tejnaksh Healthcare Ltd changed from 36 on March 2021 to 19.9 on March 2026 . This represents a CAGR of -9.41% over 6 yearsThe P/E Ratio of Transgene Biotek Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 years The Market Cap of Tejnaksh Healthcare Ltd changed from ₹ 73.94 crore on March 2021 to ₹ 24.23 crore on March 2026 . This represents a CAGR of -16.97% over 6 yearsThe Market Cap of Transgene Biotek Ltd changed from ₹ 34.7 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 years The revenue of Tejnaksh Healthcare Ltd for the Jun '26 is ₹ 2.75 crore as compare to the Mar '26 revenue of ₹ 2.69 crore. This represent the growth of 2.23% The revenue of Transgene Biotek Ltd for the Jun '26 is ₹ 0.06 crore as compare to the Mar '26 revenue of ₹ 0.2 crore. This represent the decline of -70% The ebitda of Tejnaksh Healthcare Ltd for the Jun '26 is ₹ 0.79 crore as compare to the Mar '26 ebitda of ₹ 0.85 crore. This represent the decline of -7.06% The ebitda of Transgene Biotek Ltd for the Jun '26 is ₹ -0.06 crore as compare to the Mar '26 ebitda of ₹ -0.13 crore. This represent the decline of -53.85% The net profit of Tejnaksh Healthcare Ltd changed from ₹ 0.6 crore to ₹ 0.26 crore over 9 quarters. This represents a CAGR of -31.04% The net profit of Transgene Biotek Ltd changed from ₹ 0.2 crore to ₹ -0.39 crore over 9 quarters. This represents a CAGR of NaN% The Dividend Payout of Tejnaksh Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Transgene Biotek Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Tejnaksh Healthcare Ltd

Tejnaksh Healthcare Limited was incorporated in Mumbai on 18 February, 2008 as a Private Limited Company and converted into Public Limited Company with effect from 10 March, 2015 issued by the Registrar of Companies, Mumbai, Maharashtra.
Tejnaksh runs an Institute of Urology, an ISO certified the international level Urology hospital, located in Dhule, Maharashtra.
It provides a complete range of services from consultations and investigations to treatment for Urology.
The main objective of Hospital namely Institute of Urology is to provide the people of Khandesh region of Maharashtra, the services of a super specialty hospital at an affordable rate. Initiated with a vision to strengthen healthcare in rural India, the Company started its journey from Institute of Urology, a state of the art flagship, kidney care center in Dhule in the year 2003.

About Transgene Biotek Ltd

Founded in March 1990 by Dr. Koteswara Rao, Transgene Biotek Limited was one of the first Biotechnology companies in India.
Although Transgene began life manufacturing and selling diagnostic kits, it soon moved on to true biotech research, including the research and development of vaccines, oncology , New drug delivery technologies etc.
The first major success came when it sold genetically engineered recombinant Hepatitis B vaccine technology along with novel and patented process in 1999 to the Serum Institute, Pune. Presently, the Company is engaged in the business of research and development and manufacture of various medical reagents, both chemical and immuno-diagnostic reagents for qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively.

FAQs for the comparison of Tejnaksh Healthcare Ltd and Transgene Biotek Ltd

Which company has a larger market capitalization, Tejnaksh Healthcare Ltd or Transgene Biotek Ltd?

Market cap of Tejnaksh Healthcare Ltd is 23 Cr while Market cap of Transgene Biotek Ltd is 19 Cr

What are the key factors driving the stock performance of Tejnaksh Healthcare Ltd and Transgene Biotek Ltd?

The stock performance of Tejnaksh Healthcare Ltd and Transgene Biotek Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Tejnaksh Healthcare Ltd and Transgene Biotek Ltd?

As of October 25, 2026, the Tejnaksh Healthcare Ltd stock price is INR ₹11.78. On the other hand, Transgene Biotek Ltd stock price is INR ₹2.57.

How do dividend payouts of Tejnaksh Healthcare Ltd and Transgene Biotek Ltd compare?

To compare the dividend payouts of Tejnaksh Healthcare Ltd and Transgene Biotek Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.